Either by coincidence or by design, MDA Hellas, the Muscular Dystrophy Association of Greece, is located on Elpidos Street in downtown Athens. Elpidos is Greek for “hope” — and that’s exactly what MDA Hellas offers the many neuromuscular disease patients under its care. Antigone Karras is executive manager of…
News
In the mythology of ancient Greece, Hermes was the god of boundaries and transitions, with the ability to move between the mortal and divine worlds. In modern-day Athens, Hermes Christos Athanasiou Gill is a cheerful, trilingual 7-year-old who likes math and enjoys playing Minecraft, a video game. He also has…
Treatment of Duchenne muscular dystrophy (DMD) patients with Raxone (idebenone) delays the need for assisted ventilation by three years, new data from a Phase 3 clinical trial show. Trial results also demonstrate that measuring the air flow speed in and out of the lungs, or peak expiratory flow…
Benitec Biopharma recently granted Axovant Sciences worldwide rights to its investigational AXO-AAV-OPMD gene therapy program for the treatment of oculopharyngeal muscular dystrophy (OPMD) under a global licensing agreement. AXO-AAV-OPMD is currently in preclinical development, and Axovant plans to launch a placebo-controlled trial testing the therapy candidate for OPMD…
Coping with Duchenne muscular dystrophy is difficult enough in the United States. But in neighboring Mexico, people with Duchenne often face social discrimination, lack of access to the newest therapies, a financially strapped healthcare system, and general ignorance. “Very few Mexicans know anything about this disease,” said Graciela Méndez Covarrubias,…
Acceleron’s ACE-083, for the treatment of patients with facioscapulohumeral muscular dystrophy (FSHD), has been granted orphan drug status by the U.S. Food and Drug Administration (FDA), the company announced. FSDH affects about 20,000 people in the U.S. It is a rare genetic muscle disorder for which there…
Five years after the death of a Utah boy named Mitchell Jones, the national foundation created in his name helps families struggling with the ravages of Duchenne muscular dystrophy. Mitchell, who was diagnosed with Duchenne at the age of 3, died of heart failure on March 2, 2013, just…
Phase 3 Trial of Oral Edasalonexent as Potential DMD Treatment to Open Soon, Catabasis Announces
A global Phase 3 trial evaluating the efficacy and safety of oral edasalonexent in patients with Duchenne muscular dystrophy (DMD) will begin enrolling boys, ages 4 to 7, in the coming months, Catabasis Pharmaceuticals announced. Top-line results from this trial, to be called POLARIS, are expected in April 2020, and this…
Betty Vertin had never heard of Duchenne muscular dystrophy before July 8, 2010 — the day a neurologist in Omaha, Nebraska, diagnosed her son Max with the rare disease. “Will you spell that for me?” she remembers asking the doctor through her tears. Vertin was 10 weeks pregnant when she…
With so much focus on the very real dangers of muscular, pulmonary and cardiac decline, it’s easy for moms and dads of Duchenne kids to forget about less urgent issues like dental health and digestion. But they shouldn’t, said experts speaking at Parent Project Muscular Dystrophy’s recent 2018…
Recent Posts
- MDA 2026: Early trial of PGN-EDODM1 shows biomarker activity in DM1
- As my FSHD progression worsens, I’m battling feelings of shame
- MDA 2026: Sevasemten halts functional decline in Becker trial
- MDA 2026: Keynote speaker to MDA community: ‘Your voice is powerful’
- Guest Voice: Navigating the windy road of rare disease specialists